Maze Therapeutics (MAZE) highlighted advancements in its clinical pipeline during its presentation at the Wells Fargo 21st Annual Healthcare Conference, underscoring early-stage progress on two potential therapies. The biotech company, valued at approximately $1.46 billion, reported a 5.61% drop in stock price to $24.89 on September 9, 2026, though its 1-year return remains robust at 61%, with shares trading 47% below their 52-week high of $53.65. With $495 million in cash reserves, the company extends its financial runway into 2029, maintaining a strong liquidity position.
MZE829 (APOL1 inhibitor for APOL1-Mediated Kidney Disease, or AMKD): The Phase II basket study, known as HORIZON, has demonstrated promising early results in treating AMKD across three patient subgroups—those with focal segmental glomerulosclerosis (FSGS), diabetic AMKD, and hypertensive AMKD without diabetes. In March 2026, 12 evaluable patients showed an average 36% reduction in urinary albumin-to-creatinine ratio (UACR), with 50% achieving a 30% or greater response. Notably, the FSGS subgroup saw an average 62% UACR reduction, with 75% of patients responding. Following the initial readout, the company adjusted the study protocol, lowering the UACR entry threshold to 200 mg/g and expanding enrollment in the European Union. The company anticipates completing additional HORIZON data by the end of 2026 or early 2027, with a Phase III pivotal trial planned for the first half of 2027. The estimated U.S. patient population for AMKD, particularly among West African descent, is around 250,000, including approximately 10,000 FSGS cases.
MZE782 (SLC6A19 inhibitor for phenylketonuria and chronic kidney disease): Phase I trials in healthy volunteers revealed significant urinary phenylalanine (Phe) excretion increases, with the 240 mg twice-daily dose producing a 42-fold rise. The company initiated a Phase II trial, CIPheR, testing doses of 120 mg BID, 240 mg BID, and 240 mg BID combined with a BH4 agent. Top-line Phase II PKU data are expected in 2027, with a Phase II CKD trial planned for the first half of 2027.
Maze Therapeutics’ progress contrasts with a competitive landscape where only 25 patients have been studied across two sponsors in the APOL1 field over roughly four and a half years. Competitors include Vertex, Otsuka, and AstraZeneca, with Vertex leading in the AMPLITUDE trial for inaxaplin. The company’s pipeline gains reflect strategic focus on expanding clinical evidence, positioning Maze for potential future milestones in both kidney disease and metabolic disorders.
